ATHIRA PHARMA INC (ATHA)

US04746L1044 - Common Stock

2.52  -0.19 (-7.01%)

News Image
a day ago - Athira Pharma, Inc.

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

BOTHELL, Wash., May 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on...

News Image
3 days ago - BusinessInsider

ATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Athira Pharma (NASDAQ:ATHA) just reported results for the first quarter of 2024...

News Image
3 days ago - InvestorPlace

ATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024

ATHA stock results show that Athira Pharma beat analyst estimates for earnings per share the first quarter of 2024.

News Image
3 days ago - Athira Pharma, Inc.

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates...

News Image
a month ago - Athira Pharma, Inc.

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

Experienced clinical development leader with a strong track record of advancing therapeutics from early development to approval and commercialization

News Image
a month ago - Athira Pharma, Inc.

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer....

News Image
a month ago - Athira Pharma, Inc.

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease

Fosgonimeton counteracts mechanisms of amyloid-beta (Aβ)-driven toxicity and demonstrates neuroprotection in preclinical models of Alzheimer’s disease

News Image
a month ago - Athira Pharma, Inc.

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease ...

News Image
2 months ago - Athira Pharma, Inc.

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

Presentation to highlight therapeutic potential of Athira’s small molecules targeting the neurotrophic HGF system in neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis

News Image
2 months ago - Athira Pharma, Inc.

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

Presentation to highlight therapeutic potential of Athira’s small molecules targeting the neurotrophic HGF system in neurodegenerative disorders, including...

News Image
2 months ago - Athira Pharma, Inc.

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s & Parkinson’s Diseases at AD/PD™ 2024...

News Image
3 months ago - Athira Pharma, Inc.

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates...

News Image
3 months ago - Athira Pharma, Inc.

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Results demonstrate ATH-1105 is neuroprotective, preserves motor and nerve function and extends survival in preclinical models of ALS

News Image
3 months ago - Athira Pharma, Inc.

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)...

News Image
4 months ago - Athira Pharma, Inc.

Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update

Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update...

News Image
5 months ago - Athira Pharma, Inc.

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease ...

News Image
5 months ago - Athira Pharma, Inc.

Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential...

News Image
6 months ago - Athira Pharma, Inc.

Athira Pharma to Participate in Sidoti December Small Cap Investor Conference

Company Presentation to highlight novel therapeutic candidates targeting the HGF neurotrophic system in late-stage clinical development in neurodegenerative diseases, including Alzheimer’s disease

News Image
6 months ago - Athira Pharma, Inc.

Athira Pharma to Participate in Sidoti December Small Cap Investor Conference

Company Presentation to highlight novel therapeutic candidates targeting the HGF neurotrophic system in late-stage clinical development in...

News Image
6 months ago - Athira Pharma, Inc.

Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND

Presentation to highlight preclinical data from ATH-1105, Athira’s potential treatment candidate for amyotrophic lateral sclerosis (ALS)

News Image
6 months ago - Athira Pharma, Inc.

Athira Pharma to Participate in Jefferies London Healthcare Conference

BOTHELL, Wash., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on...

News Image
8 months ago - Athira Pharma, Inc.

Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Athira Pharma presents new preclinical data on ATH-1105 for the treatment of amyotrophic lateral sclerosis (ALS)....